<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(4 Suppl 1)</volume><submitter/><journal>Gastrointestinal cancer research : GCR</journal><pagination>S20-S27</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4812840</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)</pubmed_title><pmcid>PMC4812840</pmcid></additional><is_claimable>false</is_claimable><name>Cost Effectiveness Analysis (CEA) of Bevacizumab (Bev) in 1st and 2nd-line treatment of metastatic colorectal cancer (mCRC)</name><description/><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Sep</publication><modification>2025-04-27T01:24:31.854Z</modification><creation>2025-04-06T18:10:59.655Z</creation></dates><accession>S-EPMC4812840</accession><cross_references/></HashMap>